Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Childhood cancers (all types), drawn from the whole corpus: 30 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
27 medicines on record are linked to one of the types below rather than to Childhood cancers (all types) itself. Grouped by the type that holds them; each list opens that type's own page.
Most children with cancer live where cure rates are below 30%.
Late effects affect the majority of long-term survivors.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Few new drugs are developed for children because the markets are small.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added.
Three-year event-free survival 92.
Hazard of an event 0.
Five-year event-free survival 68.
Three-year progression-free survival 87.